Biodexa has enrolled the initial two subjects in the Phase III Serenta study of eRapa, involving individuals with FAP.

Anocca has secured approximately Skr440m (around $46m) to primarily support the early-stage clinical trials of VIDAR-1.

This is the latest hit for Pfizer’s sickle cell disease portfolio after pulling Oxbryta from the market in 2024.

MASLD is among the most common types of chronic liver disease and is estimated to affect 30% of the global population.

THL Partners has announced its agreement to purchase Headlands Research, a clinical trial sites network, from KKR-managed ...

As antimicrobial resistance (AMR) escalates and chronic viral infections like human immunodeficiency virus (HIV) and herpes ...

Natera’s Signatera assay has been shown to improve outcomes in molecular residual disease (MRD)-positive patients with muscle-invasive bladder cancer (MIBC) when used as a companion diagnostic in a ...

CytomX's Phase I trial of ADC CX-2051 in colorectal cancer will continue based on a decision made by a safety committee ...

The Phase II STARLIGHT study (NCT05417126) found that a single intravitreal injection of gene-agnostic MCO-010 in six ...

According to the US Centers for Disease Control and Prevention, substance use disorder (SUD) affects approximately one in six ...

Schrödinger said it is ending development of the CHC7 inhibitor in blood cancer as both a monotherapy and combination.